Genetic screening for important variants in breast cancer patients under 60 years

• Date :
• 11    
  0

HER2 in prognosis of brain metastasis in breast cancer

• Date :
• 11    
  0

Combining radiotherapy and immunotherapy in head and neck cancer

• Date :
• 9    
  0

Liquid biopsy biomarkers for early detection and treatment prediction in HCC

• Date :
• 7    
  0

Racial disparities in breast cancer

• Date :
• 7    
  0

Clinical trials evaluating immune checkpoint blockade and radiotherapy in head and neck cancer

• Date :
• 1    
  0

Preoperative CRT improves overall survival in pancreatic cancer: long-term results of PREOPANC

• Date :
• 1    
  0

OlympiA: adjuvant olaparib in gBRCAm, HER2-negative, high-risk, early breast cancer

• Date :
• 1    
  0

Future directions in melanoma

• Date :
• 1    
  0

Liposomal irinotecan plus 5-FU & leucovorin for patients with metastatic BTC

• Date :
• 1    
  0

NIFTY: liposomal irinotecan in combination with 5FU and leucovorin in patients with mBTC

• Date :
• 1    
  0

Late-stage trials in rare sarcoma subtypes

• Date :
• 1    
  0

Targeted therapies for gastroesophageal adenocarcinoma

• Date :
• 0    
  0

PANGEA: personalized treatment strategy for patients with metastatic gastroesophageal adenocarcinoma

• Date :
• 0    
  0

What's to come in melanoma at ASCO 2021?

• Date :
• 0    
  0

Genomic profiling in HER2+ disease

• Date :
• 0    
  0

Future directions in gastrointestinal cancer

• Date :
• 0    
  0

Developmental therapeutics updates to look at for at ASCO 2021

• Date :
• 0    
  0

Biomarker testing and treatment of TRK fusion cancer in pediatric patients

• Date :
• 0    
  0

Targeted therapies for CNS tumors

• Date :
• 0    
  0

Next steps in NSCLC: checkpoint inhibitors plus cellular therapy

• Date :
• 0    
  0

RELATIVITY-047: relatlimab, an anti-LAG-3 antibody + nivolumab in first-line advanced melanoma

• Date :
• 0    
  0

FIGHT update: 1L bemarituzumab in FGFR2b+ gastric cancer

• Date :
• 0    
  0

Clinical activity of fianlimab, an anti-LAG-3 mAb combined with cemiplimab in advanced melanoma

• Date :
• 0    
  0

ARTISTRY-2: Phase I/II study of nemvaleukin alfa in solid tumors

• Date :
• 0    
  0

Abemaciclib in patients with p16ink4a negative, relapsed mesothelioma

• Date :
• 0    
  0

Oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma

• Date :
• 0    
  0

PREDICT+ underestimates survival of patients with HER2+ early breast cancer

• Date :
• 0    
  0

Mortality in cancer patients with COVID-19: a systematic review

• Date :
• 0    
  0

Elevated alpha-fetoprotein in aHCC patients and increased responsiveness to ramucirumab

• Date :
• 0    
  0

Phase I INSIGHT platform trial: eftilagimod alpha with avelumab in advanced solid tumors

• Date :
• 0    
  0

PREVENT: preventive HIPEC in combination with perioperative FLOT for gastric cancer

• Date :
• 0    
  0

Rebastinib plus paclitaxel shows encouraging anti-tumor activity in endometrial cancer

• Date :
• 0    
  0

Larotrectinib in adult and pediatric patients with TRK fusion-positive primary CNS tumors

• Date :
• 0    
  0

Overall survival in the Phase II CodeBreaK 100 trial in NSCLC

• Date :
• 0    
  0

Evolving applications of ctDNA in lung cancer: MRD, early detection, and molecular profiling

• Date :
• 0    
  0

PARPi for somatic BRCA1/2 and other DNA repair gene mutations in women with metastatic breast cancer

• Date :
• 0    
  0

Checkpoint inhibitors - alone or with chemotherapy in lung cancer?

• Date :
• 0    
  0

EV-103: enfortumab vedotin and pembrolizumab in urothelial carcinoma

• Date :
• 0    
  0

Blood and tissue TMB in predicting response to immunotherapy

• Date :
• 0    
  0

Surgical outcomes from the Phase III CheckMate 816 trial

• Date :
• 0    
  0

Neoadjuvant therapy is taking off in lung cancer

• Date :
• 0    
  0

ctDNA as a diagnostic, prognostic, and predictive biomarker for lung cancer

• Date :
• 0    
  0

Colorectal cancer trial updates at ASCO 2021

• Date :
• 0    
  0

Is minimally invasive surgery the way forward in lung cancer?

• Date :
• 0    
  0

CheckMate 920: nivo plus ipi for advanced RCC with brain metastases

• Date :
• 0    
  0

Predicting treatment responses with CTCs in ccRCC

• Date :
• 0    
  0

Natural history of patients with advanced CCA with FGFR2 gene alterations or wild-type FGFR2

• Date :
• 0    
  0

Future directions in bile duct cancers

• Date :
• 0    
  0

Chemo-immunotherapy in patients with locally advanced gastroesophageal cancer

• Date :
• 0    
  0

Equal opportunities for access to expert medical centers across all patients with sarcoma

• Date :
• 0    
  0

Lifileucel in advanced melanoma

• Date :
• 0    
  0

LUMINOS-101: PVSPRIO plus pembrolizumab in recurrent glioblastoma

• Date :
• 0    
  0

VISION: 177Lu-PSMA-617 in PSMA-positive mCRPC

• Date :
• 0    
  0

BOS172738 in RET-altered tumors

• Date :
• 0    
  0

Immune markers predict overall survival in BC patients with brain metastases

• Date :
• 0    
  0

Ribociclib plus everolimus in advanced dedifferentiated liposarcoma

• Date :
• 0    
  0

Trastuzumab deruxtecan in patients with breast cancer and brain metastases in DESTINY-Breast01

• Date :
• 0    
  0

Impact of the tumor immune microenvironment on bevacizumab benefit in colon cancer

• Date :
• 0    
  0

How low can we go? Treating ER+ and TNBC with HER2-targeting agents

• Date :
• 0    
  0

PI3K inhibitors for the treatment of brain metastases in HER2-negative breast cancer

• Date :
• 0    
  0

Most anticipated data in the breast cancer space at ASCO 2021

• Date :
• 0    
  0

Breast cancer advances in 2021

• Date :
• 0    
  0

Phase 2 study of DRD2 antagonist/ClpP agonist ONC201 in NETs

• Date :
• 0    
  0

Patritumab deruxtecan in patients with EGFR-mutant NSCLC

• Date :
• 0    
  0

Underrepresented in medicine: training as a Latin American woman

• Date :
• 0    
  0

5-year survival outcomes from the PACIFIC trial

• Date :
• 0    
  0

Pembrolizumab versus high-dose interferon or ipilimumab in high-risk resected melanoma

• Date :
• 0    
  0

ASCO Daily News Plenary Update - LBA1: OlympiA

• Date :
• 0    
  0

ASCO Daily News Plenary Update - LBA2: JUPITER-02

• Date :
• 0    
  0

ASCO Daily News Plenary Update - LBA3: OUTBACK

• Date :
• 0    
  0

ASCO Daily News Plenary Update - LBA4: VISION

• Date :
• 0    
  0

ASCO Daily News Plenary Update - LBA5: KEYNOTE-564

• Date :
• 0    
  0

Vascularised lymph node transfer in patients with cancer treatment-related lymphoedema

• Date :
• 0    
  0

FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRC

• Date :
• 0    
  0

Outcomes from ADAPT-HR-/HER2+ evaluating dual HER2 blockade

• Date :
• 0    
  0

Phase I/II study of a novel SERCA in ER+ HER2- BC

• Date :
• 0    
  0

Long-term follow-up results from JAVELIN Merkel 200 and KEYNOTE-017 in MCC

• Date :
• 0    
  0

Progression patterns in post-ipilimumab and anti-PD-1 in metastatic melanoma

• Date :
• 0    
  0

Evaluating the prognostic value of PSMA PET/CT in mCRPC

• Date :
• 0    
  0

Abiraterone in metastatic castration-sensitive prostate cancer

• Date :
• 0    
  0

Potential treatment approaches for breast cancer with brain metastases

• Date :
• 0    
  0

Tucatinib in HER2+ breast cancer with leptomeningeal metastases

• Date :
• 0    
  0

CheckMate 238: nivolumab versus ipilimumab in stage III melanoma

• Date :
• 0    
  0

Investigating EGFR resistance mutations in routine genomic profiling

• Date :
• 0    
  0

Lu-PSMA-617 deployment and future of prostate cancer treatment

• Date :
• 0    
  0

ENSURE: impact of surveillance after esophageal cancer surgery on quality-of-life

• Date :
• 0    
  0

Beyond anti-PD-1 and anti-CTLA-4 in melanoma

• Date :
• 0    
  0

Unanswered questions in PSMA-targeted radionuclide therapy

• Date :
• 0    
  0

Results from PEACE-1: abiraterone in mCSPC

• Date :
• 0    
  0

FORT-2: rogaratinib and atezolizumab in urothelial cancer

• Date :
• 0    
  0

Phase II trial of lenvatinib for anaplastic thyroid cancer

• Date :
• 0    
  0

Maintenance therapy in urothelial carcinoma

• Date :
• 0    
  0

Predictions for thyroid cancer in the next 10 years

• Date :
• 0    
  0

Cabozantinib shows efficacy against previously treated differentiated thyroid cancer

• Date :
• 0    
  0

IMpower010: adjuvant atezolizumab improves DFS in resected stage II-IIIA NSCLC

• Date :
• 0    
  0

24mg versus 18mg starting dose of lenvatinib for differentiated thyroid cancer

• Date :
• 0    
  0

HER2CLIMB-04: tucatinib plus T-DXd for HER2+ breast cancer

• Date :
• 0    
  0

Larotrectinib, a TRK inhibitor for patients with solid tumors

• Date :
• 0    
  0

Lifileucel, a novel TIL in melanoma

• Date :
• 0    
  0

Comparing therapy benefit from initially HER2 positive or negative metastatic breast cancer patients

• Date :
• 0    
  0

CADMUS trial: multiparametric ultrasound in prostate cancer diagnosis

• Date :
• 0    
  0

The IMMULAB trial: pembrolizumab with local ablation for patients with early-stage HCC

• Date :
• 0    
  0

Personalized medicine in NETs

• Date :
• 0    
  0

Enfortumab vedotin in urothelial cancer

• Date :
• 0    
  0

Head and neck cancer highlights at ASCO 2021

• Date :
• 0    
  0

Where does immunotherapy fit in the treatment landscape of sarcoma?

• Date :
• 0    
  0

Long term AEs in PSMA-TRT

• Date :
• 0    
  0

Next steps in MCC: new targets and tacking PD-1 resistance

• Date :
• 0    
  0

The Duma Lab: Investigating social justice, gender bias and racial discrimination in medicine

• Date :
• 0    
  0

Progress in treatment approaches for patients with melanoma

• Date :
• 0    
  0

ARAMIS: darolutamide in patients with nmCRPC

• Date :
• 0    
  0

Phase I/II dose-escalation study of 225Ac-J591 in progressive mCRPC

• Date :
• 0    
  0

CheckRad-CD8: checkpoint blockade + RT dependent on intratumoral CD8+ T-cell infiltration in HNSCC

• Date :
• 0    
  0

Nivolumab plus bevacizumab in recurrent glioblastoma

• Date :
• 0    
  0

Immune checkpoint inhibitors in urothelial bladder cancer

• Date :
• 0    
  0

Final results from ClarIDHy: ivosidenib in IDH1-mutated CCA

• Date :
• 0    
  0

JAVELIN Bladder 100: duration of treatment-free interval

• Date :
• 0    
  0

NETTER-1 update: 177Lu-DOTATATE in patients with midgut neuroendocrine tumors

• Date :
• 0    
  0

Lung cancer updates at ASCO 2021

• Date :
• 0    
  0

Final OS from NETTER-1: lutetium-177-DOTATATE in patients with midgut NETs

• Date :
• 0    
  0

Genitourinary cancer trial updates at ASCO 2021

• Date :
• 0    
  0

The future of NSCLC treatment

• Date :
• 0    
  0

Adjuvant and neoadjuvant immunotherapy in MCC

• Date :
• 0    
  0

Advances in esophageal cancer and unanswered questions

• Date :
• 0    
  0

Phase I trial of ruxolitinib with radiation and temozolomide in newly diagnosed glioma/glioblastoma

• Date :
• 0    
  0

Novel therapeutic approaches in glioblastoma: CAR-T therapy & BBB modulation

• Date :
• 0    
  0

TNO155 in advanced solid tumors

• Date :
• 0    
  0

Drug repurposing in HER2+ breast cancer

• Date :
• 0    
  0

Initial report from NCCAPS on hospitalized cancer patients with COVID-19

• Date :
• 0    
  0

Phase I/II trial of zenocutuzumab for tumors with NRG1 fusions

• Date :
• 0    
  0

Updated overall efficacy and safety of selpercatinib in patients with RET fusion+ NSCLC

• Date :
• 0    
  0

OlympiA: adjuvant olaparib following chemo significantly improves IDFS

• Date :
• 0    
  0

Bispecific antibodies in lung cancer

• Date :
• 0    
  0

Eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma.

• Date :
• 0    
  0

Targeted therapy versus standards of care in metastatic NSCLC

• Date :
• 0    
  0

Optimizing treatment approaches for the management of GIST

• Date :
• 0    
  0

FDG-PET avidity as a prognostic biomarker in RCC

• Date :
• 0    
  0

VISION: Lu-177-PSMA-617 in mCRPC

• Date :
• 0    
  0

Improving the stratification of prostate cancer

• Date :
• 0    
  0

FIGHT-202: pemigatinib in CCA

• Date :
• 0    
  0

Implementing biomarker-driven strategies in RCC

• Date :
• 0    
  0

FIGHT-202: pemigatinib for FGFR2 altered CCA

• Date :
• 0    
  0

OPTIMA II: de-escalating therapy in HPV-positive oropharyngeal cancer

• Date :
• 0    
  0

Treatment de-escalation in head and neck cancer

• Date :
• 0    
  0

Future research in multiparametric imaging for prostate cancer diagnosis

• Date :
• 0    
  0

CheckMate 649: 1L nivo + chemotherapy improves OS

• Date :
• 0    
  0

Molecular testing in cost-effective targeted therapies

• Date :
• 0    
  0

Cardiac safety in the APHINITY study

• Date :
• 0    
  0

Prostate cancer updates at ASCO 2021

• Date :
• 0    
  0

Sotorasib: first targeted approval for KRAS G12C mutated NSCLC

• Date :
• 0    
  0

Lung cancer trial updates at ASCO 2021

• Date :
• 0    
  0

Subgroup analyses in the CLEAR study of lenvatinib plus pembrolizumab versus sunitinib in RCC

• Date :
• 0    
  0

Hot topics in sarcoma at ASCO 2021

• Date :
• 0    
  0

Trial updates in prostate cancer from ASCO 2021: VISION, PEACE1, & SWOG S1216

• Date :
• 0    
  0

Activity of EGFR TKIs in patients with NSCLC with uncommon EGFR mutations

• Date :
• 0    
  0

NSCLC highlights from ASCO 2021

• Date :
• 0    
  0

CheckMate 648: 1L IO-IO in advanced esophageal squamous cell carcinoma

• Date :
• 0    
  0

Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer

• Date :
• 0    
  0

Top news in breast cancer from ASCO 2021

• Date :
• 0    
  0

44e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse

• Date :
• 4186    
  0

14èmes Journées des Référentiels en Soins Oncologiques de support - AFSOS 2024

• Date :
• 3846    
  0

Post ASCO-ESMO 2024 Fédération Francophone de Cancérologie Digestive

• Date :
• 3178    
  0

45emes Journées de la Société Française de Sénologie et de Pathologie Mammaire - SFSPM 2024

• Date :
• 6931    
  0

Molecular Analysis for Precision Oncology Congress - MAP 2024

• Date :
• 2506    
  0